JP2021505546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505546A5 JP2021505546A5 JP2020529346A JP2020529346A JP2021505546A5 JP 2021505546 A5 JP2021505546 A5 JP 2021505546A5 JP 2020529346 A JP2020529346 A JP 2020529346A JP 2020529346 A JP2020529346 A JP 2020529346A JP 2021505546 A5 JP2021505546 A5 JP 2021505546A5
- Authority
- JP
- Japan
- Prior art keywords
- nicotine
- orally disintegrating
- tablet
- tablet according
- disintegrating nicotine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 118
- 229960002715 nicotine Drugs 0.000 claims description 107
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 107
- 239000003826 tablet Substances 0.000 claims description 96
- 239000000843 powder Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 210000003296 saliva Anatomy 0.000 claims description 8
- 206010057852 Nicotine dependence Diseases 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 claims description 6
- 229920005862 polyol Polymers 0.000 claims description 5
- 150000003077 polyols Chemical class 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000003456 ion exchange resin Substances 0.000 claims description 3
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920006318 anionic polymer Polymers 0.000 claims description 2
- 229960004874 choline bitartrate Drugs 0.000 claims description 2
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 239000006190 sub-lingual tablet Substances 0.000 claims description 2
- 229940098466 sublingual tablet Drugs 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- 239000000905 isomalt Substances 0.000 claims 1
- 235000010439 isomalt Nutrition 0.000 claims 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- SKZDZXPBBYUFBY-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCCC1C1=CC=CN=C1 SKZDZXPBBYUFBY-WLHGVMLRSA-N 0.000 description 1
- QLDPCHZQQIASHX-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 QLDPCHZQQIASHX-UHFFFAOYSA-N 0.000 description 1
- AIBWPBUAKCMKNS-UHFFFAOYSA-N 2-carboxyphenolate;3-(1-methylpyrrolidin-2-yl)pyridin-1-ium Chemical compound OC(=O)C1=CC=CC=C1O.CN1CCCC1C1=CC=CN=C1 AIBWPBUAKCMKNS-UHFFFAOYSA-N 0.000 description 1
- SDVKWBNZJFWIMO-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O SDVKWBNZJFWIMO-UHFFFAOYSA-N 0.000 description 1
- VWTHFJXLFGINSW-PPHPATTJSA-N 2-hydroxypropanoic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound CC(O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 VWTHFJXLFGINSW-PPHPATTJSA-N 0.000 description 1
- WDXYLGOIULBYAB-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine perchloric acid Chemical compound Cl(=O)(=O)(=O)O.N1=CC=CC(=C1)C1N(C)CCC1 WDXYLGOIULBYAB-UHFFFAOYSA-N 0.000 description 1
- MMOPGICOOYBFJU-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.CN1CCCC1C1=CC=CN=C1 MMOPGICOOYBFJU-UHFFFAOYSA-N 0.000 description 1
- FFYVQVZXWDGRAY-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;hydrate Chemical compound O.CN1CCCC1C1=CC=CN=C1 FFYVQVZXWDGRAY-UHFFFAOYSA-N 0.000 description 1
- HDJBTCAJIMNXEW-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;hydrochloride Chemical compound Cl.CN1CCCC1C1=CC=CN=C1 HDJBTCAJIMNXEW-UHFFFAOYSA-N 0.000 description 1
- BXZYRJUYZVFANZ-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;zinc;hydrate Chemical compound O.[Zn].CN1CCCC1C1=CC=CN=C1 BXZYRJUYZVFANZ-UHFFFAOYSA-N 0.000 description 1
- MQWJVKLIBZWVEL-XRIOVQLTSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.CN1CCC[C@H]1C1=CC=CN=C1 MQWJVKLIBZWVEL-XRIOVQLTSA-N 0.000 description 1
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 description 1
- SXIBJSDOZKYORQ-UHFFFAOYSA-N 4-methylbenzenesulfonic acid 3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound S(=O)(=O)(O)C1=CC=C(C)C=C1.N1=CC=CC(=C1)C1N(C)CCC1 SXIBJSDOZKYORQ-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- YHBIGBYIUMCLJS-UHFFFAOYSA-N 5-fluoro-1,3-benzothiazol-2-amine Chemical compound FC1=CC=C2SC(N)=NC2=C1 YHBIGBYIUMCLJS-UHFFFAOYSA-N 0.000 description 1
- GJMKJBHRQDGHMT-UHFFFAOYSA-N C(C=CC=CC)(=O)O.N1=CC=CC(=C1)C1N(C)CCC1 Chemical compound C(C=CC=CC)(=O)O.N1=CC=CC(=C1)C1N(C)CCC1 GJMKJBHRQDGHMT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- VAUQRLHPXWYZRZ-PPHPATTJSA-N benzoic acid 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)c1ccccc1.CN1CCC[C@H]1c1cccnc1 VAUQRLHPXWYZRZ-PPHPATTJSA-N 0.000 description 1
- JDIZODRSTZHAFD-UHFFFAOYSA-N butanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)CCC(O)=O.CN1CCCC1C1=CC=CN=C1 JDIZODRSTZHAFD-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ZDBSZLXHLZRTGL-UHFFFAOYSA-N dodecanoic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.CCCCCCCCCCCC(O)=O ZDBSZLXHLZRTGL-UHFFFAOYSA-N 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- FGAFEHZTRRYNDF-UHFFFAOYSA-L zinc;3-(1-methylpyrrolidin-2-yl)pyridine;dichloride Chemical compound [Cl-].[Cl-].[Zn+2].CN1CCCC1C1=CC=CN=C1 FGAFEHZTRRYNDF-UHFFFAOYSA-L 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201770925 | 2017-12-08 | ||
| DKPA201770925 | 2017-12-08 | ||
| PCT/DK2018/050335 WO2019110072A1 (en) | 2017-12-08 | 2018-12-07 | Nicotine tablet |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505546A JP2021505546A (ja) | 2021-02-18 |
| JP2021505546A5 true JP2021505546A5 (https=) | 2022-01-04 |
| JP7278281B2 JP7278281B2 (ja) | 2023-05-19 |
Family
ID=64744343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529346A Active JP7278281B2 (ja) | 2017-12-08 | 2018-12-07 | ニコチン錠 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11738016B2 (https=) |
| EP (2) | EP3906916A1 (https=) |
| JP (1) | JP7278281B2 (https=) |
| CN (1) | CN111447921B (https=) |
| AU (1) | AU2018378648B2 (https=) |
| CA (1) | CA3085062C (https=) |
| DK (1) | DK3720418T3 (https=) |
| ES (1) | ES2890975T3 (https=) |
| PL (1) | PL3720418T3 (https=) |
| WO (1) | WO2019110072A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3085065C (en) | 2017-12-08 | 2023-12-05 | Fertin Pharma A/S | Formulations providing high nicotine concentrations |
| WO2019110072A1 (en) | 2017-12-08 | 2019-06-13 | Fertin Pharma A/S | Nicotine tablet |
| US12433321B2 (en) | 2019-12-09 | 2025-10-07 | Nicoventures Trading Limited | Oral composition with beet material |
| US12439952B2 (en) | 2019-12-09 | 2025-10-14 | Nicoventures Trading Limited | Moist oral compositions |
| US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
| US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
| US11617744B2 (en) | 2019-12-09 | 2023-04-04 | Nico Ventures Trading Limited | Moist oral compositions |
| US12310959B2 (en) | 2019-12-09 | 2025-05-27 | Nicoventures Trading Limited | Oral compositions with reduced water content |
| US11969502B2 (en) | 2019-12-09 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
| US12520867B2 (en) | 2019-12-09 | 2026-01-13 | Nicoventures Trading Limited | Buffered oral compositions |
| US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
| US12439949B2 (en) | 2019-12-09 | 2025-10-14 | Nicoventures Trading Limited | Oral compositions with reduced water activity |
| CA3181912A1 (en) | 2020-06-08 | 2021-12-16 | Anthony Richard Gerardi | Effervescent oral composition comprising an active ingredient |
| US11382861B1 (en) * | 2020-12-17 | 2022-07-12 | Nirajkumar Karneshbhai Patel | Nicotine pouch |
| MX2023015529A (es) | 2021-06-25 | 2024-03-05 | Nicoventures Trading Ltd | Productos orales y metodo de fabricacion. |
| JP2024530905A (ja) | 2021-07-30 | 2024-08-27 | ニコベンチャーズ トレーディング リミテッド | 微結晶性セルロースを含むエアロゾル生成基材 |
| CA3233375A1 (en) | 2021-09-30 | 2023-04-06 | Michael Zawadzki | Oral product with a basic amine and an ion pairing agent |
| CN113827575A (zh) * | 2021-11-02 | 2021-12-24 | 上海普康药业有限公司 | 一种利伐沙班片剂及其制备方法 |
| CN115969898A (zh) * | 2023-02-09 | 2023-04-18 | 东莞市吉纯生物技术有限公司 | 一种防治口腔溃疡的口含烟含片及其制备方法 |
| EP4543417A1 (en) | 2023-09-12 | 2025-04-30 | Fertin Pharma A/S | Orally disintegrating nicotine tablet for use under lip |
| WO2025056129A1 (en) | 2023-09-12 | 2025-03-20 | Fertin Pharma A/S | Orally disintegrating nicotine tablet for use under lip |
| DK202430540A1 (en) | 2024-09-12 | 2026-03-26 | Fertin Pharma As | Orally disintegrating nicotine tablet with reduced sweetener content |
| WO2026057139A1 (en) | 2024-09-12 | 2026-03-19 | Fertin Pharma A/S | Fast dissolvable solid oral dosage form |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866046A (en) | 1988-05-31 | 1989-09-12 | Top Laboratories, Inc. | Low-dosage sublingual aspirin |
| GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| US5549906A (en) | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
| US5810018A (en) * | 1994-12-29 | 1998-09-22 | Monte; Woodrow C. | Method, composition and apparatus for reducing the incidence of cigarette smoking |
| CA2348452A1 (en) | 1998-10-27 | 2000-05-04 | Biovail Technologies Ltd. | Microparticles containing peg and/or peg glyceryl esters |
| US20010016593A1 (en) | 1999-04-14 | 2001-08-23 | Wilhelmsen Paul C. | Element giving rapid release of nicotine for transmucosal administration |
| US6248760B1 (en) | 1999-04-14 | 2001-06-19 | Paul C Wilhelmsen | Tablet giving rapid release of nicotine for transmucosal administration |
| US6583160B2 (en) | 1999-04-14 | 2003-06-24 | Steve Smith | Nicotine therapy method and oral carrier for assuaging tobacco-addiction |
| US6544552B2 (en) | 2001-01-11 | 2003-04-08 | Particle And Coating Technologies, Inc. | Method of producing porous tablets with improved dissolution properties |
| AU2002237548B2 (en) * | 2001-03-06 | 2007-04-05 | Kyowa Hakko Kogyo Co., Ltd. | Intraorally rapidly disintegrable tablet |
| NZ530439A (en) | 2001-04-20 | 2004-11-26 | Lavipharm Lab Inc | Intraoral delivery of nicotine for smoking cessation |
| US20060057207A1 (en) | 2001-11-30 | 2006-03-16 | Pfizer Inc | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
| SE0104388D0 (sv) | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| US20150080442A1 (en) | 2003-02-24 | 2015-03-19 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
| EP2343045A3 (en) * | 2003-02-24 | 2011-09-21 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
| BRPI0412752B8 (pt) | 2003-07-24 | 2021-05-25 | Glaxosmithkline Llc | composição de filme de dissolução oral |
| US7387788B1 (en) * | 2003-10-10 | 2008-06-17 | Antares Pharma Ipl Ag | Pharmaceutical compositions of nicotine and methods of use thereof |
| WO2005055945A2 (en) * | 2003-12-08 | 2005-06-23 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
| US20070196474A1 (en) | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly disintegrating low friability tablets comprising calcium carbonate |
| ES2403167T3 (es) | 2005-12-21 | 2013-05-14 | Basf Se | Polivinilpirrolidona entrelazada finamente dividida como agente desintegrador de tabletas |
| US20070269492A1 (en) * | 2006-05-16 | 2007-11-22 | Per Steen | New product and use and manufacture thereof |
| US20070269386A1 (en) | 2006-05-16 | 2007-11-22 | Per Steen | New product and use and manufacture thereof |
| CN101516426A (zh) | 2006-09-27 | 2009-08-26 | 尼克诺姆股份公司 | 定向用途 |
| BRPI0719428A2 (pt) | 2006-12-01 | 2014-02-25 | Cima Labs Inc | Forma de dosagem transmucosal oral sólida, método para tratar dependência de nicotina em um receptor que deseja tal tratamento, sistema de distribuição de nicotina transmucosal oral, e, método de substituíção de nicotina. |
| US20080286340A1 (en) | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered nicotine containing products |
| US20080286341A1 (en) | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered coated nicotine containing products |
| WO2009007771A1 (en) | 2007-07-06 | 2009-01-15 | Gumlink A/S | High volume compressed chewing gum tablet |
| CL2009001025A1 (es) * | 2008-05-01 | 2010-09-24 | Smithkline Beecham Corp | Composicion de pastilla para chupar que comprende: a) un granulo patron con al menos: un agente tampon alcalino, un modificador de la disolucion y una carga, b) un principio activo de nicotina definido extragranular y al menos un agente tampon alcalino; procedimiento de preparacion; util para eliminar o reducir el uso de tabaco. |
| SI2177213T1 (sl) | 2008-09-17 | 2013-03-29 | Siegfried Ltd. | Nikotin vsebujoč granulat |
| ES2592882T3 (es) | 2008-10-14 | 2016-12-02 | Mcneil Ab | Forma de dosificación intra-oral de múltiples porciones y uso de la misma |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| CN107252419A (zh) | 2010-12-22 | 2017-10-17 | 巴斯夫欧洲公司 | 快速崩解的固体包衣剂型 |
| SE535587C2 (sv) | 2011-03-29 | 2012-10-02 | Chill Of Sweden Ab | Produkt innehållande ett fritt nikotinsalt och en ej vattenlöslig påse |
| TW201318650A (zh) | 2011-11-02 | 2013-05-16 | Hua Yu Wuxi Pharmaceutical Co Ltd | 口崩片組成物 |
| WO2013091631A1 (en) * | 2011-12-22 | 2013-06-27 | Fertin Pharma A/S | Method of releasing nicotine from chewing gum |
| US20130177646A1 (en) | 2012-01-05 | 2013-07-11 | Mcneil Ab | Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance |
| US11779045B2 (en) * | 2013-10-03 | 2023-10-10 | Altria Client Services Llc | Dissolvable-chewable exhausted-tobacco tablet |
| DK3166563T3 (da) | 2014-07-08 | 2021-02-15 | Fertin Pharma As | Oralt administrationssystem omfattende to rum |
| US20170172995A1 (en) | 2015-09-08 | 2017-06-22 | Venkateswara Rao Repaka | Pharmaceutical compositions of Nicotine and process for preparation thereof |
| US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
| WO2017117575A1 (en) | 2015-12-30 | 2017-07-06 | Next Generation Labs, LLC | Nicotine replacement therapy products comprising synthetic nicotine |
| CA3085065C (en) | 2017-12-08 | 2023-12-05 | Fertin Pharma A/S | Formulations providing high nicotine concentrations |
| CA3085066C (en) | 2017-12-08 | 2024-01-09 | Fertin Pharma A/S | Formulations providing high nicotine concentrations |
| WO2019110073A1 (en) | 2017-12-08 | 2019-06-13 | Fertin Pharma A/S | Solid oral nicotine formulation |
| WO2019110072A1 (en) | 2017-12-08 | 2019-06-13 | Fertin Pharma A/S | Nicotine tablet |
| CA3085064C (en) | 2017-12-08 | 2023-10-24 | Fertin Pharma A/S | Nicotine mouth spray |
-
2018
- 2018-12-07 WO PCT/DK2018/050335 patent/WO2019110072A1/en not_active Ceased
- 2018-12-07 PL PL18821992T patent/PL3720418T3/pl unknown
- 2018-12-07 JP JP2020529346A patent/JP7278281B2/ja active Active
- 2018-12-07 US US16/213,641 patent/US11738016B2/en active Active
- 2018-12-07 EP EP21182000.6A patent/EP3906916A1/en active Pending
- 2018-12-07 CN CN201880078877.9A patent/CN111447921B/zh active Active
- 2018-12-07 ES ES18821992T patent/ES2890975T3/es active Active
- 2018-12-07 AU AU2018378648A patent/AU2018378648B2/en active Active
- 2018-12-07 DK DK18821992.7T patent/DK3720418T3/da active
- 2018-12-07 EP EP18821992.7A patent/EP3720418B1/en active Active
- 2018-12-07 CA CA3085062A patent/CA3085062C/en active Active
-
2023
- 2023-07-07 US US18/348,891 patent/US12005058B2/en active Active
-
2024
- 2024-04-29 US US18/649,759 patent/US12433881B2/en active Active
-
2025
- 2025-09-23 US US19/337,441 patent/US20260014135A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505546A5 (https=) | ||
| JP2021505617A5 (https=) | ||
| JP5497435B2 (ja) | 多層口腔内崩壊錠剤 | |
| CA2834327C (en) | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence | |
| JP4989733B2 (ja) | 口腔内崩壊錠 | |
| JP5421775B2 (ja) | オキシコドンを含む顆粒及び口腔内崩壊錠剤 | |
| EP3549585B1 (en) | Orally disintegrating tablet of edoxaban tosylate hydrate | |
| ME02081B (me) | Tanke pločice buprenorfina za terapiju zamjene droge | |
| WO2006103418A1 (en) | New pharmaceutical compositions useful in the treatment of pain | |
| WO2007086457A1 (ja) | 乾式直打速崩壊性錠剤 | |
| TWI556823B (zh) | 含阿卡波糖之口崩解錠 | |
| JP2018118966A (ja) | ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。 | |
| JP2011246428A (ja) | 口腔内崩壊型医薬品及びその製造方法 | |
| JP6838632B2 (ja) | 固形製剤 | |
| KR20210118164A (ko) | 필름 코팅 조성물 및 고형 제제 | |
| US12589070B2 (en) | Low-dosage orodispersible opioid tablet and method for preparing same | |
| JP3637968B1 (ja) | 胃内崩壊性錠剤 | |
| JP2009179603A (ja) | 口腔内速崩壊性錠剤及びその製造方法 | |
| Gupta et al. | True MDTS: Mouth disintegrating tablets or mouth dissolving tablets, a comparative study | |
| JP2017052755A (ja) | 固形製剤 | |
| RU2022129278A (ru) | Твердый пероральный никотиновый состав | |
| HK40009938A (en) | Orally disintegrating tablet of edoxaban tosylate hydrate | |
| WO2002092058A1 (fr) | Preparation solide se desintegrant rapidement | |
| BR102014003686A2 (pt) | composição farmacêutica oral estável | |
| BR102013032395A2 (pt) | Composição farmacêutica oral estável |